Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

BioPharma Credit (LSE: BPCR)

Last close As at 21/11/2024

0.96

— 0.00 (0.00%)

Market capitalisation

USD1,258m

Latest Insights

View More

Investment Companies | Review

Biopharma Credit — A quality dividend play with FY22 yield of 12%

Investment Companies | edison tv

BioPharma Credit – executive interview

Investment Companies | Update

Biopharma Credit — New transaction of up to US$50m

Investment Companies | Update

Biopharma Credit — Fully invested after recent transactions
Visit Website

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (0.2) (0.6) (3.4)
Relative (4.2) (9.7) (4.8)
52 week high/low US$1.0/US$0.9

Overview

BioPharma Credit (BPCR) is on track to deliver a strong (possibly record-high) annual NAV total return (TR) in FY22 on the back of a high investment level in H122, rising interest rates benefiting its floating rate loans, as well as healthy prepayment and make-whole fees from the early loan repayments in recent months. This has allowed BPCR to announce a US$0.045 special dividend, which implies a 12.0% dividend yield for FY22 on the current share price. The above-mentioned fees also provide BPCR with a good income runway for the re-deployment of prepayment proceeds. Since being fully invested in August 2018, BPCR achieved a net NAV TR of c 8% per year.

Research

Review

Investment Companies

Biopharma Credit — Invests in Epizyme and Akebia

edison tv

Investment Companies

Bitesize briefing – BioPharma Credit

Investment Companies

Review

Biopharma Credit — High investment volume in H219

Review

Investment Companies

BioPharma Credit — New debt investment in OptiNose

Review

Investment Companies

BioPharma Credit — Debt and equity investment in BDSI

Review

Investment Companies

Biopharma Credit — Oversubscribed offering fuels further growth

Update

Investment Companies

Biopharma Credit — Leading lender in life sciences

thematic

Investment Companies

Emerging markets – Worthy of consideration

thematic

Investment Companies

Dynam Capital at the 2024 Vietnam ESG Conference

thematic

Investment Companies

UK stock market – Scope for further upside in UK large-cap stocks

thematic

Investment Companies

Listed private equity – Performing a balancing act

thematic

Investment Companies

European equities

thematic

Investment Companies

Listed Private Equity

thematic

Investment Companies

Vietnamese equities: Due a comeback?

thematic

Investment Companies

Investment companies: Latin America is worthy of consideration

thematic

Consumer

IPO apocalypse

thematic

TMT

ESG, moving beyond the box tick

thematic

Investment Companies

The case for US capital markets

thematic

Investment Companies

Value Investing: Living with the reality, waiting for the inevitable

thematic

Consumer

Illuminator: August Update

thematic

Investment Companies

Post Woodford- A spotlight on smaller company liquidity

thematic

Investment Companies

How to buy and sell investment trusts

thematic

Investment Companies

Types of investment trusts

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Investment Companies

Investment Trusts Quarterly: Biotechnology & healthcare trusts

thematic

Investment Companies

Investment Trusts Quarterly: Growth and income